This story establishes the small scope of the story up high. It brings in one outside voice and is more cautious than the other two stories in describing the number of people affected by corneal conditions. It also is the only story to use a dollar figure when discussing the costs and to put an actual number to the degree of improvement in people’s vision. The story would have received a higher score had it explained a little bit more about the study’s limitations and explained how this procedure likely will not be available for many years, if ever.
This story was similar to the Reuters story but packed in more information and did not rely largely on the press release. It shows that even with limited space and time, a reporter can pull together the relevant facts to present readers with most of the context they need.
This is the only story of the three reviewed to discuss costs. As for cost, Griffith said the biosynthetic corneas "in theory" should be cheaper than donated corneas. Griffith said a German study recently found that donated corneas cost about $2,500.
The benefits are quantified about as well as in the other two stories, and the story avoids putting the benefits in relative terms. The one big advantage of this story is that it puts a number to the vision improvement. "We were pleasantly surprised that in six patients, vision improved from about 20/400 to 20/100, meaning that these patients could see objects four times farther away than before the operation," said Griffith, director of the Integrative Regenerative Medicine Center at Linkoping University in Sweden.
The story explains that there were no adverse side effects. It should have been clear that the patients were followed for two years.
The story does a better job than the Reuters story but not as good a job as WebMD in evaluating the quality of the evidence. It could have provided more details about the limitations of the study.
The story avoids disease mongering and actually presents a more conservative estimate of the number of people affected by corneal disorders. An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.
The story includes one independent source who is basically a booster for the research. He also, though, raises an issue that underscores some of the information lacking in the story. The story also could have explained what the funding sources were.
The story does compare the treatment to human corneal transplants. It could have talked about plastic corneas, too. Dr. Mark J. Mannis, the one independent source in the story refers to a "repertoire of corneal transplant surgeons." What else is in that repertoire? It would be nice to know, and it would be even nicer to know how this procedure stacks up against the other options in terms of costs and benefits.
The only hint that this research is preliminary is toward the end when the story says, The next step in research, Griffith said, is to create a "new generation" of cornea implants and test them on a wider variety of patients. This actually sounds actually more optimistic than the comments from Griffith in the press release, leading one to believe that she was more cautious than this sentence implies.
The novelty of the procedure is not established.
The story goes beyond the news release, but, like the Reuters story, does not actually present the evidence with the same caveats and caution that come through in the news release and in the WebMD story.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like